

宁毅简历

联系方式:

Email: Yi.Ning@vip.163.com

电话: 0898-66891302

地址: 海南省海口市龙华区学院路3号

教育

哈佛大学公共卫生学院博士 Harvard T.H. Chan School of Public Health, Doctor of Science 2010

专业: 营养学 (第二专业生物统计和流行病)

领域: 营养流行病

导师: Edward Giovannucci and Frank Hu (教授和院士)

论文: 代谢紊乱和癌症风险

华盛顿大学公共卫生硕士 University of Washington, Master of Public Health, 2003

专业: 流行病

导师: Michelle Williams, (院士、现任哈佛大学公卫学院院长, 原华盛顿大学教授)

论文: 生活方式和妊娠毒血症和高血压

北京大学医学部 (原北京医科大学) 医学学士 1993

专业: 预防医学

职业培训

领导力和管理, 美国管理协会, 证书 2014-2018

消灭脊髓灰质炎理论和实践, 日本国际协力事业团, 证书 1997

残疾预防的病人教育、消灭麻风、问题导向管理等, 国际麻风病协会, 证书 1998

大流感预警, 哈佛大学, 证书 2007

经验

海南医学院公共卫生学院院长和教授, 第一附属医院教授 12/2021-Present

- 管理上, 组织制定和落实公共卫生学院发展规划, 针对海南自贸岛公共卫生建设提供教学、科研和公共卫生服务支持。业务上, 研究多病共患的病因学研究, 并寻找可改变的生活方式和新技术创新。同时, 辅导和支持海南医学院附属医院的临床科研工作。

中国卫生政策和管理学会 China Health Policy and Management Society, 咨询顾问 10/2021 – 12/2021

- 这是 2009 年作为联合创始人创立的一家 NGO 学术组织, 促进中美之间公共卫生学者之间的交流, 定期在中美召开学术会议, 出版 China Health Review 《中国健康评论》等。

北京智源人工智能研究院 (BAAI) 健康研究中心主任和首席科学家

05/2021 – 10/2021

- 是科技部和北京市政府支持，北大、清华、百度、小米和字节跳动等创立的高科技企业。主要是筹建团队，探索和促进世界前沿智能技术在医药卫生领域的应用。

A股上市企业美年大健康副总裁、首席科学家和研究院院长

05/2018 – 04/2021

提供这家 700 家体检机构，最高市值 800 亿人民币，年服务 3000 万人次体检的上市公司提供研究和学术的管理和支持。

- 其中作为首席科学家，筹建生物样本库获得证监会审核通过 (23.75 亿人民币)；
- 作为项目负责人获得科技部国家重点研发计划健康体检大数据云平台构建 (2020YFC2003400)，项目总金额 6607 万元；
- 作为组织者，获得国家重点研发计划“无创性脑血流灌注功能定量评估系统研发及临床验证研究”项目；
- 作为骨干专家，获得国家自然科学基金重大研究计划集成项《面向人群健康和重大疾病的大数据集成共享平台研究及示范应用，2019-2022》
- 2018 年 5 月以来，和央媒一起发布《新华指数.体检大数据糖尿病地图》和《新华指数.心血管健康报告》和《中国城市健康报告等》等一系列有影响的传播健康白皮书。
- 新冠疫情期期间，百篇科普阅读量数十亿次，为 CCTV 英文台 CGTN、东方卫视和凤凰卫视等解读疫情近三十余次等，单篇科普文章超 1.5 亿人次阅读量，单次视频讲座超 200 万观众。
- 作为专家，参与国家卫计委、财政部、中科院和中国工程院一系列疫情控制研究。
- 以专家身份参与撰写多部国家级指南和评估标准。
- 与同伴共同创立美国华人教授学者组成的 China Health Policy and Management Society 会员达 5000 多人，并担任 China Health Review Prospective 部分主编以及多个杂志审稿人，多位学生在美国正教授 (终身) 或总监以上高管，数十位博士毕业生活跃于医药领域。

北京大学医学部美年公众健康研究院执行院长和教授

中关村美年健康产业研究院执行院长

05/2018 – 04/2021

- 建立中国健康体检大数据研究平台，开展学术研究，为北京大学、协和医科大学、北京中医药大学、首都医科大学、安徽医科大学等提供教学和科研平台，制定体检管理规程
- 支持北京大学开设大数据和流行病学课程，辅导北京大学、协和医科大学等机构硕士、博士和博士后研究、辅导，支持中日友好医院等开展临床科研工作。

葛兰素史克医药研发中心学部委员和流行病学总监

11/2013 – 05/2018

- 曾参与或领导设计超 15 个呼吸、神经和传染病药物临床研究 (Closed Triple, Benlysta, Relvar, Anora, Repinirole, Dolutegravir, and Avamys 等)，其中卫生经济学研究项目盐酸罗匹尼罗研究创造了中国新药上市进入国家医保的最快纪录 (7 个月)。
- 参与创立了 GSK-清华全球健康中心 (GSK-Thinghua Center for Global Health) 和 GSK 传染病和公共卫生研究院 (Institute for Infectious Disease and Public Health) (2016 年)，开展超级细菌治疗、乙肝根治、耐药结核的治疗等世界尖端研究。
- 因发明真实世界数据找新药方法，成为 GSK 多年来累计 63 最高学术职位 Senior Fellow 学部委员 (5/2017)。

- 作为博士后导师，开设博士后课程“医学大数据”。(请参见文末GSK的通告祝贺信件评价)，多次获得葛兰素史克的银奖铜奖等。
- 设计和推动了中国和葛兰素史克历史上最大的真实世界数据研究（与钟南山院士合作）
- 设计和推动了EAST研究，了解呼吸药物上市后安全性和有效性（Effectiveness and Safety of Tenofovir Disoproxil Fumarate (EAST study): A 3-Year, Prospective, Registry Study;
- 作为研发中心的唯一临床医生培训讲师，开展临床科研培训。
- 角色和研究领域从流行病、到真实世界研究、到卫生经济学研究，到战略发展等。

弗吉尼亚联邦大学梅西癌症中心副教授和临床营养首席科学家

弗吉尼亚联邦大学流行病学和营养学终生系列助理教授、博士生导师和博士后导师 **01/2010 – 10/2013**

- **教学课程：**流行病学基础、营养流行病学、肿瘤流行病学、慢性病、应用统计分析、预防医学
- **临床研究：**
 - 作为首席科学家，建立肿瘤研究群组Day and Night Study For Cancer Survivors 研究影响癌症患者生存的营养、运动、心理等可改变的因素；
 - 研究超胖儿童的减肥，根据全美肥胖儿童生长曲线变化，建立了青少年在快速体重增长期的减肥评价方法。
 - 研究放疗、化疗和手术后治疗癌症病人的生活方式干预，提高治疗效果、减少副作用、减少复发、提高生活质量，延长寿命。
- **社会服务：**博士录取委员会委员，新教工录用委员会委员，开展的肿瘤病人和肿瘤医生的培训活动受到MSNBC, ABC, Fox News 的报道。

哈佛大学公卫学院 博士生研究员

08/2003 – 12/2009

在世界著名的Project Viva 和Channing Division of Network Medicine (Former Channing Laboratory)开展研究

- 在两个大的研究群组Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) 研究病人的生活方式、生物标记物和早期临床症状，特别是代谢和生长因子通路上相关的因素。
- 领导组织和制定Project Viva对妊娠毒血症和妊娠高血压的研究方案，并落实研究。

华盛顿大学硕士研究员/瑞典医学中心研究助理

05/2001 – 07/2003

- 在两个群组研究Omega and Alpha Studies 研究孕产期疾病；
- 研究非洲地区的传染病流行。

国家卫生部（卫健委）疾病控制局（防疫司）公务员

05/1994 - 06/2001

- 国家首批考录公务员，先后从事疾病控制的综合计划和管理、计划免疫和慢性病控制。
- 与 WHO, World Bank, UNICEF, CDC、JICA等多变和双边组织合作，开展疾病控制管理。
- **综合计划管理**
 - 参与组织建立和开展疾病预防控制机构的审评
 - 参与组织建立了全国第一个应用型公共卫生硕士教育项目，培养了国家疾病控制的中坚力量
- **计划免疫项目管理**
 - 世行VII项目：Expanded Program of Immunization part (US\$ 87,951,500), China Disease Prevention Program (World Bank Health VII) Project in China (Total US\$ 166 millions);
 - 国家计划免疫冷链建设项目
 - 脊髓灰质炎流行病学监测、病毒学监测和管理系统运转，被世界卫生组织成为最好的监测系统。
 - 参与领导并确保了成功消灭了脊髓灰质炎
- **非传染性疾病控制**

- 启动了国家营养和疾病调查，同时组织专家撰写了国内第一批慢性病，包括高血压、糖尿病、肿瘤防治的指南。
- 多次获得卫生部的表彰

- 其它

世界银行奖学金支持到华盛顿大学进修学习传染病

JICA和WHO支持到University of Tokyo和JICA学习控制传染病和消灭脊髓灰质炎

北京医科大学（现北京大学医学部）

08/1993 – 05/1994

留校任教，并参与卫生部卫生管理研究所的建立，为国家政府部门提供公共卫生咨询建议

以往的学生

Kirsten Kerrick (Formal post-doc student、博士后)

Program Director, National Cancer Institute, USA 目前美国国立卫生研究院癌症研究所项目主任

Shibing Yang (Former PhD student、博士学生)

Director of Value Evidence and Outcomes, GlaxoSmithKline, USA 现葛兰素史克总监

Marieka A. Helou, M.D., M.P.H, (Former MPH student、硕士学生) 现为教授和大学研究中心主任

Professor and Clinical Director of Pediatric Hematology and Oncology Inpatients

Director of Pediatric Hematology and Oncology Fellowship Program

Director of Pediatric M3 Clerkship, Virginia Commonwealth University, USA

Qin Shen (Former PhD student、博士学生) 现为葛兰素史克副总监

Director of Value Evidence and Outcomes, Analytics and Innovation, GlaxoSmithKline, USA

Allison Phillips Bell (Former MPH student) 硕士学生，现为大学研究项目主任

Clinical Research Director, Carilion Clinic

Susan Cha (Formal PhD student) 博士学生，现为美国疾病预防控制中心流行病学家，EIS官员

EIS officer and Epidemiologist at Centers for Disease Prevention and Control, USA

Joseph Engda (Formal trainee)

Epidemiologist at California Department of Public Health, USA

Allssa Troeschel (Former MPH student、硕士学生)

PhD in Emory University, USA 现为美国疾病预防控制中心流行病学家，EIS官员

Pu Jing (Formal post-doc fellow) (博士后普京 现为昆明生物所科研副处长)

Director of Innovation and technology, Kunming Biological Institute

Meng Xin (Formal post-doc fellow) (博士后孟醒 现为科兴副总监)

Associate Director, Kexing Biological Company

Ren Yi (Formal post-doc fellow) (博士后任怡 现为恒瑞副总监)

Associate Director, Henrui Pharmaceutical Company

Xianglin Lv (Formal post-doc fellow) (博士后吕香霖 现为葛兰素史克副总监)
Associate Director, GlaxoSmithKline R&D

Guanqiao Li (Formal post-doc fellow) (博士后李冠乔现为清华大学讲师)
Faculty Member, Tsinghua University School of Medicine

Edmond Trey Wickham, M.D. (硕士生 现为教授)
Professor, Program Director, Fellowship Program in Endocrinology and Metabolism
Director of Research, Healthy Lifestyles Center

部分荣誉

- 2018 Mayor's consultant in Guilin 国务院桂林市建设国家可持续发展议程创新示范区智库专家
- 2019 Deputy Chairman of Health Examination Committee of Health Promotion Foundation
中国健康促进基金会健康体检中心建设与发展专项基金专家委员会副主任委员
- 2017 GSK Senior Fellow (the highest academic position. Total 63 in GSK history by 2018).
GSK最高学术职位也是荣誉职位
- 2016 Silver Recognition Award of GSK. GSK银奖
- 2016 Bronze Recognition Award of GSK. GSK铜奖
- 2015 Speaker of **TEDxLujiazui**, independently organized by TED event: Big-Data Changes Future Medicine. TEDx演讲者
- 2015 Speaker Award, International Chinese Statistics Association. 中国统计学会讲师奖
- 2014 Annual Bronze Recognition Award of GSK. GSK年度铜奖
- 2012 News release of Association for Cancer Research AACR 2012 Scientific Session. AACR新闻发布
- 2011 Poster Award of American Society of Hematology 53rd Annual Conference [LINK HERE](#).
美国血液病年会壁报奖
- 2004 - 2009 Harvard University James K Knox Fellowship Award [LINK HERE](#). 哈佛大学奖学金
- 2001 - 2003 University of Washington Merit-Based Graduate Fellowship Award 华盛顿大学教学奖
- 1998 World Bank Scholar Award. 世界银行学者奖
- 1998 China Ministry of Health Medical Officer of the Year. 卫生部优秀公务员
- 1997 Japanese International Cooperation Agency Scholar Award. JICA学者奖
- 1993 University of North Carolina & Peking University Scholar Award.
美国北卡罗林纳大学和北京大学奖学金
- 1989 - 1993 Peking University Excellent Student Awards (Annually). 北京大学优秀学生奖学金

职业会员

- 2019-至今 中国健康促进会健康体检基金会副主任委员
- 2010 – 2014 American Association for Cancer Research (Professor-level Active Member.)
美国癌症协会教授会员
- 2010 – 2013 Co-founder and Board Director, China Health Policy and Management Society.
CHMPAMS 创始人和董事会成员
- 2015 – Present Board Member, China Geriatrics Society. 中国老年病学学会理事
- 2008 – 2013 American Association for the Advancement of Science. 美国科学院会员
- 2005 – 2013 American Diabetes Association. 美国糖尿病学会会员
- 2002 – 2010 Society for Epidemiologic Research. 美国流行病学学会会员
- 2002 – 2009 Society for Pediatric and Perinatal Epidemiologic Research. 美国儿童流行病学学会会员
- 2005 – 2007 American Heart Association/American Stroke Association. 美国心脏病学会会员

EDITORIAL REVIEWER AND EDITOR AND COMMITTEE MEMBER

两个年度分会主席**Chair**, Prevention Chapter with 14 sessions in Great Wall International Congress of Cardiology 2020 and Asian Heart Society Congress 2020. Expected in Oct 19-26, 2020 (The largest medical conference in China)

杂志编辑 **Public Health Academic Editor**, Engineering, 2020

学术编辑 **Academic Editor**: Public Library of Science One, 2013-2018

版面编辑 **Prospective Editor**: China Health Review, 2010-2013

哈佛公卫学院亚洲俱乐部主席 **Chair of Asian Club**: Harvard School of Public Health, 2005-2006

会议主办成员 **Member of Program Committee**, 2014 Quantitative Science Forum: Quantitative Drug Evaluation in and, Beyond Clinical Trials, Drug Information Association

杂志审稿人, 杂志包括:

Atherosclerosis, American Journal of Preventive Medicine, American Journal of Public Health, British Journal of Nutrition, Cancer, Cancer Cause Causation, European Journal of Clinical Nutrition (EJCI), Journal of National Cancer Institute (JNCI), Journal of Immigrant and Minority Health, Metabolism, North American Journal of Medicine & Science, Obesity Reviews, PLOS One, The Oncologist, Annals of Epidemiology, etc.

媒体访谈专家

近百家媒体, 包括CCTV英文频道CGTN, 东方卫视、人民日报健康客户端、保健时报、科技日报、北京日报、财经、新华社、纽约时报、ABC News, MSNBC, FoxNews, CBS News, Science Daily, Cancer Research UK, Nurse, WebMD, China Academy of Science, China Health Daily, People's Daily, Xinhua News, China Global Television Network(CGTN), Phoenix TV, Dragon TV etc.

2018-2022 RESEARCH GRANTS (国内部分)

1. 科技部国家重点研发计划体检大数据平台构建 RMB 66,700,000元 宁毅 Yi Ning (PI)
角色: 牵头人和首席科学家 National Key Fund for Health Cloud Platform
2. 科技部国家重点研发计划无创脑血流灌注项目 RMB 1,052,000元 王波 Bo Wang (PI)
角色: 支持研究院PI同事申请和开展项目 National Key Fund for MEI Research (Collaborator)
3. 美年大健康上市公司生物样本库增资项目 RMB 2,375,000,000元 宁毅 Yi Ning (PI)
角色: 牵头人和首席科学家 Company's BioBank (PI)
4. 牵头科技部主动健康和主动应对重点专项《老年人多病共患临床大数据综合管理共享平台建设和防治策略研究》, 2020-2022 National Key Fund for Aging Population (Collaborator)
角色: 主要参与者
5. 国家自然科学基金国家重大项目医疗健康大数据国家自然科学基金“大数据驱动的管理与决策研究”重大研究计划集成项目《面向人群健康和重大疾病的大数据集成共享平台研究及示范应用》, 2018
角色: 主要合作者 National Health Data Collaboration (Key contributor)
6. 科技部国家重点研发项目《糖尿病眼病人工智能诊断云平台》, 2019
角色: 主要合作者 National Key Fund for Eye Disease Research (Collaborator)
7. 牵头科技部数字诊疗装备重点研发专项《消化道胶囊机器人研发和应用项目》, 2020
角色: 合作单位负责人 National Key Fund for Robot in Digestive Track (Collaborator)

2010-2013 RESEARCH GRANTS (国外部分)

- Tobacco Indemnification and Community Revitalization Commission US \$612,126 Ning Y (PI)
Day and Night Lifestyle and Cancer Survival Study (Awarded)
July 2010-June 2014
The goal of this study is to identify obesity and other lifestyle factors associated with quality of life and survival in cancer patients.
PI: Ning
- Tobacco Indemnification and Community Revitalization Commission US \$2,391,000 Ning Y (Co-PI)
Disease Management of Cancer Survivors (Awarded)
July 2010-June 2014
The goal is to improve quality of life of cancer survivors and their survival through medical treatment and intervention.
PI: Ginder
- Massey Cancer Center US \$30,000 Ning Y (PI)
Genetic Variants, Diabetes and Adverse Late Effects of Radiation Therapy (Awarded)
July 2013-June 2014
The goal of this study is improve quality of life of head and neck cancer patients with radiation-induced injury.
PI: Ning
- Massey Cancer Center Multi-investigator grant US \$100,000 Ning Y (Co-PI)
Genetic risk to smoking addiction and lung cancer (Awarded)
Sept 2013-Aug 2014
The goal of this study is to use genetic factors influencing smoking to discover genes influencing the development of lung cancer and to test these newly identified factors in lung cancer risk assessment.
Multiple PI: Ning and Chen
- Robert Wood Johnson Foundation US \$219,312 Ning Y (Collaborator)
Evaluating the Effectiveness of School-Based BMI Notification Policies (Awarded)
Jan 2011-Jan 2013
The goal of this project is to evaluating the effectiveness of school-based BMI notification for adolescent obesity control.
PI: Mazzeo
- China Medical Board (a Boston-based foundation) US \$58,500 Ning (Co-PI)
Initiation of China Health Policy and Management Society (Awarded)
The goal of this project is to set up academic network for china health professionals
PI: Zhang
- Tenure-track Faculty Start-up Award (Awarded) US \$250,000 Ning Y (PI)
PI: Ning
- University Mentor Award US \$160,000 Ning Y (PI)
PI: Ning
- Pending Grants by Oct 2013**
- American Cancer Society US\$727,000 Ning Y (PI)
Prediction of Adverse Late Effects of Radiation Therapy (ALERT study)
July 2014-June 2017
The goal is to investigate effects of genetic factors and medication use for development of radiation-induced injury using data from a multicenter radiation study and Massey Cancer Center.
PI: Ning

NIH/VCU/CCTR KL2 US\$288,750 Ning Y (PI)
Genetic variants, metformin use, and adverse late effects of radiation therapy
July 2014-June 2016
The goal is to investigate effects of genetic factors and medications for development of radiation-induced injury.
PI: Ning

NIH/R21 US\$275,000 Ning Y (PI)
Diet and Lifestyle intervention of Head and Neck Cancer patients
Dec 2014-Dec 2016
The study is a clinical trial to investigate to effects of lifestyle intervention on quality of life of head and neck cancer patients with radiotherapy.
PI: Ning

NIH/R21 US\$275,000 Ning Y (PI)
Genetic study of Lung Cancer in non-smokers
Dec 2014-Dec 2016
The study is a multi-center study to investigate to genetic factors of lung cancer in non-smokers.
PI: Chen

PEER-REVIEWED PUBLICATIONS:

1. Wang S, Song Y, Qin W, Jin C, Song Y, Jia P, Ning Y, Li L, Six air pollutants associated with increased risk of thyroid nodules: a study of 4.9 million Chinese adults. *Front Endocrinol (Lausanne)*. 2021 Dec 13;12:753607. doi: 10.3389/fendo.2021.753607 (Corresponding author).
2. Zhang Y Tong M, Wang B, Shi, Z Li L, Lu T, Ning Y. Geographical, gender and seasonal variation of diabetes prevalence: a nationwide study among 1.4 million participants who attend physical examination. *J Clin Endocrinol Metab*. 2021 Nov 19;106(12):e4981-e4992. (Corresponding author)
3. Bao H, Jin C, Wang S. Song Y, Xu Z, Yan X; Li L, **Ning Y**, Wang H. Prevalence of cervicovaginal Human Papillomavirus infection and genotypes in the pre-vaccination era of China: a nationwide population-based study based on 427,401 women. *J Infect*. 2021 Apr;82(4):75-83. doi: 10.1016/j.jinf.2021.02.017. Epub 2021 Feb 18. (Corresponding author)
4. Shan R, **Ning Y***, Ma Y, Gao X, Zhou Z, Jin C, Lv Jun, Liming Li*. Incidence and risk factors of hyperuricemia among 2.5 million Chinese adults during the years 2017-2018. *International Journal of Environmental Research and Public Health*, 2021 Feb 28;18(5):2360. doi: 10.3390/ijerph18052360.PMID: 33671018
5. Shan R, **Ning Y**, Yuan Ma Y, Liu S, Wu J, Fan X, Lv J, Wang B, Li S Ning Y, Li L. Prevalence and risk factors of atrioventricular block among 15 million Chinese health examination adults in 2018. *BMC Cardiovasc Disorders*. 2021 Jun 11;21(1):289. doi: 10.1186/s12872-021-02105-3
6. Wu J, Lv J, Gao Y, Jin C, Shan R, Wang B, Gao X, Ning Y, Li L. Prevalence and risk factors of MRI-defined brain infarcts in 1.4 million health check-up population in China. *International Journal of Environmental Research and Public Health*, 19 Apr 2021, 18(8) DOI: 10.3390/ijerph18084325 PMID: 33921763 PMCID: PMC8072670.
7. Man S, Gao Y, Lv J, Jin C, Pan W, Wei H, Wang B, Li L, **Ning Y**. Establishment of reference intervals of ten commonly used clinical chemistry analytes: a real-world study in China. *Biomark Med*. 2021 May 6. doi: 10.2217/bmm-2021-0233. Online ahead of print. PMID: 33955784
8. Wu J, Ning Y, Gao Y, Malik V, Shan R, Lv J, Li L. Association between ambient air pollution and MRI-defined brain infarcts in health examinations in China. *Int. J. Environ. Res. Public Health* 2021, 18(8), 4325; <https://doi.org/10.3390/ijerph18084325> (Corresponding author)
9. Li Y, Jin C, Li J, Tong M, Wang M, Huang J, **Ning Y**, Ren G. Prevalence of Thyroid Nodules in China: A Health Examination Cohort-Based Study. *Front Endocrinol (Lausanne)*. 2021 May 26;12:676144. doi: 10.3389/fendo.2021.676144.
10. Wang P, Ning Y, Shan R, Wu J, Wang B, Gao Y, Ma Y, Zhang Y, Lv J, Li L. Association between fasting plasma glucose trajectories and osteoporosis in 18,624 diabetic and non-diabetic Chinese participants. (submitted and revised)
11. Huang T, Tong M, Wang B, Clarke R, Li L, Ning Y. Burden and correlates of chronic kidney disease in Chinese adults. (Corresponding author) submitted.
12. Liu L, Ma Y, Jin J, Pan X, Wang B, Ning Y. *Normal ranges, and variation in intraocular pressure by sex, age, and geographic location in China: A nationwide study of 284,937 adult*. (Corresponding author) submitted.
13. Man S, Ma Y, Jin C, Lv J, Tong M, Wang B, Li L, **Ning Y**. Association between Helicobacter pylori infection and diabetes, a cross-sectional study in China. *Journal of Diabetes Reseahyprch*. 2020 Sep 24;2020:7201379. doi: 10.1155/2020/7201379. eCollection 2020. (**corresponding author**)
14. Wang B, Xu L, Li Q, Man S, Jin C, Liu L, Zhan S, **Yi Ning**. Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies. *BMC Cancer* volume 20, 1021 (2020) (**corresponding author**)

15. Man S, Gao Y, Lv J, Jin C, Pan W, Wei H, Wang B, Ning Y, Li L. Estimating the case fatality ratio of the COVID-19 epidemic in China. *Biomarkers in Medicine*, 2021 (accepted, corresponding author)
16. Tong M, Man S, Jin C, Wu J, Shan R, Gao Y, Wang B, Yang L, Ning Y, Li L. Prevalence, Awareness, Treatment and Control of Hypertension: a survey of 10 million adults. *Chinese Journal of Circulation*. 2020, 35(9): 866-872.
17. Wang S, Ning Y, Li L, Experience and challenges in health big data application, *Chinese Journal of Epidemiology*. 2020, 41(3): 303-309. 王胜锋, 宁毅, 李立明. 健康医疗大数据互联互通模式的经验与挑战[J]. *中华流行病学杂志*, 2020, 41(3): 303-309
18. Man S, Ma Y, Jin C, Lv J, Tong M, Wang B, Li L, **Ning Y**. Association between *Helicobacter pylori* infection and diabetes, a cross-sectional study in China. *Journal of Diabetes Research*. 2020: 7201379. doi: 10.1155/2020/7201379 (**corresponding author**)
19. Cui J, Zhang L, Yang, Zhu Y, Fang H, Chen B, Guo L, Wu Y, Xu T, Yu L, Zhang Q, Shao Y, Ning Y, Zhang H. The Prognostic Significance of the Treatment Response of Regional Lymph Nodes and the Refinement of Current TNM Staging System in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy (October 11, 2019). Available at SSRN: <https://ssrn.com/abstract=3468378> or <http://dx.doi.org/10.2139/ssrn.3468378>
20. Yang S, Chen X, Wang L, Wu T, Fei T, Zhang G, **Ning Y**, Jia P. Walkability indices and childhood obesity: A review of epidemiologic evidence. *Obesity Reviews*, June 2020. Online ahead of print <https://doi.org/10.1111/obr.13096> (**corresponding author**)
21. Wang Z, Zhao L, Huang Q, Hong A, Yu C, Xiao Q, Zou B, Ji S, Zhang L, Zou K, **Ning Y**, Zhang J, Jia P. Traffic-related environmental factors and childhood obesity: a systematic review and meta-analysis. *Obesity Reviews*. 2020 Jan 30. doi: 10.1111/obr.12995.
22. Zhao H, Man S, Wang B, **Ning Y**. Epidemic size of novel coronavirus-infected pneumonia in the Epicenter Wuhan: using data of five-countries' evacuation action. *MedRxiv*. Feb 13, 2020. 20022285 doi: <https://doi.org/10.1101/2020.02.12.20022285> (**corresponding author**).
23. Wang X, Ma Z, **Ning Y**, Chen C, Chen R, Chen Q, Zhang H, Li C, He Y, Wang T, Tong C, Wu J, Li Y, Ma H, Zhang S, Zhao H. Estimating the case fatality ratio of the COVID-19 epidemic in China. *medRxiv* Feb 17, 2020. 20023630; doi: <https://doi.org/10.1101/2020.02.17.20023630>.
24. Su K, Xu L, Li G, Ruan X, Li X, Deng P, Li X, Li Q, Chen X, Xiong Y, Lu S, Qi L, Shen C, Tang W, Rong R, Hong B, **Ning Y**, Long D, Xu J, Shi X, Yang Z, Zhang Q, Zhuang Z, Zhang L, Xiao J, Li Y. Forecasting influenza activity using self-adaptive AI model and multi-source data in Chongqing, China. *EBioMedicine*. 2019 Sep;47:284-292.
25. Zhao H, **Ning Y**, Cooper J, Refoios Camejo R, Ni X, Yi B, Parks D. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. *Adv Ther*. 2019 Jun;36(6):1252-1265.
26. Rafie C, **Ning Y**, Wang A, Gao X, Houlihan R. Impact of physical activity and sleep quality on quality of life of rural residents with and without a history of cancer: findings of the Day and Night Study. *Cancer Manag Res*. 2018 Nov 9;10:5525-5535. doi: 10.2147/CMAR.S160481. eCollection 2018 (PI of the study)
27. **Ning Y**, Zhang C. High consumption of potatoes may increase risk of developing type 2 diabetes, *BMJ*, 2016; 352. doi: <https://doi.org/10.1136/bmj.h6898>.
28. Alam A, Mukhopadhyay N, **Ning Y**, Reshko LB, Cardnell R, Alam O, Rabender CS, Yakovlev VS, Walker L, Anscher MS, Mikkelsen BS, A Preliminary Study on Racial Differences in HMOX1, NFE2L2 and TGFβ1 Gene

Polymorphisms and Radiation Induced Late Normal Tissue Toxicity, International Journal of Radiation Oncology, Biology, Physics. doi:10.1016/j.ijrobp.2015.05.049 (4.2).

29. Rafie C, **Ning Y**, Wang A, Gao X, Houlihan R. Impact of physical activity and sleep quality on quality of life of rural residents with and without a history of cancer: findings of the Day and Night Study. *Cancer Manag Res*. 2018 Nov 9;10:5525-5535. doi: 10.2147/CMAR.S160481. eCollection 2018 (**PI of the study cohort**)
30. Wang G, Divall S, Radovick S, **Ning Y**, Paige D, Hong X, Caruso D, Pearson, Wang MC Zuckerman B, Cheng T, Wang X. Elevated Cord Blood Insulin Levels in Preterm Births Persist into Early Childhood: Evidence of Prematurity on Metabolic Programming. *JAMA*. 2014;311(6):587-596. doi:10.1001/jama.2014.1 (35.3).
31. Zhang C, Li Y, Malhotra A, **Ning Y**, Gao X. Restless legs syndrome status as a predictor for lower physical function. *Neurology*. 2014 Mar 5 (8.3).
32. De Vito K., Li Y., Malhotra A., Batool-Anwar S., **Ning Y.**, Han J., Gao X, Prospective study of obesity, hypertension, high cholesterol and risk of Restless Legs Syndrome, *Movement Disorder*, 2014 Jul;29(8):1044-52. doi: 10.1002/mds.25860. Epub 2014 Apr 21 (5.7).
33. Kristin L. Schneider, Christopher Andrews, Kathleen M. Hovey, Rebecca A. Seguin, Todd Manini, Michael J. LaMonte, Karen L. Margolis, Molly E. Waring, **Yi Ning**, Stacy Sims, Yunsheng Ma, Judith Ockene, Marcia L. Stefanick and Sherry L. Pagoto. Change in physical activity after a diabetes diagnosis: An opportunity for intervention. *Medicine & Science in Sports & Exercise*, 2014 Jan;46(1):84-91. doi: 10.1249/MSS.0b013e3182a33010(4.0).
34. **Kim RB***, Phillips A, Herrick K, Helou M, Rafie C, Anscher M, **Ning Y**. Physical Activity and Sedentary Behavior in Cancer Survivors: Findings from NHANES. *PLoS ONE*, 2013, 8(3): e57598. doi:10.1371/journal.pone.0057598 (3.2) (**corresponding author**)
35. **Engeda J***, Mezuk B, Ratliff S, and **Ning Y**. Sleep and Diabetes Status: Evidence from NHANES. 2013, *Diabetic Medicine*. (2013) 30, 676–680 (3.1) (***mentored student, corresponding author**).
36. **Helou M***, **Ning Y**. Massey G, Francis G, Godder K, Laver J. Vitamin D Deficiency in Children with Cancer. *J Pediatr Hematol Oncol*. 2013 Jul 3. (1.0) (***Mentored student, received award from American Society of Clinical Oncology Meeting**).
37. Song Y, Yeung E, Liu A, VanderWeele TJ, Chen L, Liu C, Schisterman EF, **Ning Y**, Zhang C. Pancreatic Beta-cell function and type 2 diabetes risk: quantify the causal effect using a Mendelian randomization approach based on meta-analyses. *Human Mole Genet* 2012, 2012 Aug 29. (6.8).
38. Ji J, Sundquist K, **Ning Y**, Kendler KS, Sundquist J, Chen X, Incidence of Cancer in Patients with Schizophrenia and their first-degree Relatives: a Population-Based Study in Sweden, *Schizophrenia Bulletin* 2013 May;39(3):527-36. doi: 10.1093/schbul/sbs065. Epub 2012 Apr 20. (8.7).
39. Kabat GC, Kim MY, Strickler HD, Shikany JM, Lane D, Luo J, **Ning Y**, Gunter MJ, Rohan TE, A longitudinal study of serum insulin and glucose levels in relation to colorectal cancer risk among postmenopausal women, *British Journal of Cancer*, 2012 Jan 3;106(1):227-32. doi: 10.1038/bjc.2011.512.(4.8).
40. **Ning Y**, Yang S, Evans R, Stern M, Sun S, Francis G, Wickham EP III. Determinants of Weight Loss among Overweight and Obese Children Enrolled in a Multidisciplinary Weight Management Program, *European Journal of Nutrition*, 2013 Nov 10.(3.8).
41. Zhang C, **Ning Y**. Impact of dietary and lifestyle factors on the risk for gestational diabetes: Review focusing on epidemiologic evidence. *American Journal of Clinical Nutrition*, May 25, 2011 as doi: 10.3945/ajcn.110.001032.(6.8).

42. Gao X, **Ning Y**. Cancer and Parkinson's Disease: the odd couple, *Drugs of Today*, 2011 Mar;47(3):215-22 (1.2). (Invited commentary)
43. Bean MK, Mazzeo SE, Stern M, Evans R, Bryan D, **Ning Y**, Wickham EP III, Laver J, Six month dietary and metabolic changes in ethnically diverse, obese adolescents participating in a multidisciplinary weight management program, *Clinical Pediatrics*, 2011 May;50(5):408-16. Epub 2011 Jan 10. (1.2).
44. **Ning Y.**, Wang L., Giovannucci EL., Meta-analysis and systematic review of body adiposity and colorectal cancer, results from 56 observational studies, *Obesity Reviews*, 2010; 11; 19-30 (**corresponding author**) (9.0).
45. Oken E, **Ning Y**, Rifas-Shiman S, Rich-Edwards JW, Olsen SF, Gillman MW, Diet during pregnancy and risk for gestational hypertension or preeclampsia. *Annals of Epidemiology* 2007 Sep;17(9):663-668 (3.2).
46. Oken E, **Ning Y**, Rifas-Shiman SL, Radesky JS, Rich-Edwards JW, Gillman MW. Associations of physical activity and inactivity before and during pregnancy with glucose tolerance. *Obstet Gynecol*. 2006 Nov;108(5):1200-1207 (5.2).
47. Noble A, **Ning Y**, Woelk GB, Mahomed K, Williams MA. Preterm delivery risk in relation to maternal HIV infection, history of malaria and other infections among urban Zimbabwean Women. *Cent Afr J Med*. 2005 May-Jun;51(5-6):53-58 (1.7).
48. Pham L, Woelk GB, **Ning Y**, Madzime S, Mudzamiri S, Mahomed K, Williams MA. Seroprevalence and risk factors of syphilis infection in pregnant women delivering at Harare Maternity Hospital, Zimbabwe. *Cent Afr J Med*. 2005 Mar-Apr; 51(3-4): 24-30 (1.7).
49. Ogbonna C, Woelk GB, **Ning Y**, Mudzamiri S, Mahomed K, Williams MA. Maternal mid-arm circumference and other anthropometric measures of adiposity in relation to infant birth size among Zimbabwean women. *Acta Obstet Gynecol Scand*. 2007;86(1):26-32 (2.4).
50. **Ning Y**, Williams MA, Butler CL, Muiy-Rivera M, Ihunnaya O, Frederick I, Sorensen T. Maternal recreational physical activity is associated with plasma leptin concentrations in early pregnancy, *Human Reproduction*. 2005 Feb; 20(2): 382-389. (**corresponding author**) (4.7).
51. Muiy-Rivera M, **Ning Y**, Sorensen K, Luthy D, Michelle A. Williams. Leptin, Soluble Leptin Receptor and Leptin-Gene Polymorphism in Relation to Preeclampsia Risk. *Physiological Research*. 2005; 54(2):167-174. (1.5).
52. **Ning Y**, Williams MA, Vadachkoria Z, Muiy-Rivera M, Frederick I, Luthy D. Maternal Plasma Concentrations of Insulin-Like Growth Factor-1 and Insulin-Like Growth Factor Binding Protein-1 in Early Pregnancy and Subsequent Risk of Preeclampsia: A Prospective Study. *Clinical Biochemistry*, 2004 Nov; 37(11): 968-973. (2.2) (**corresponding author**).
53. **Ning Y**, Williams MA, Muiy-Rivera M, Luthy D, Leiseinring W. Maternal Plasma Leptin and the Risk of Preeclampsia: A Prospective Study. *J Maternal-Fetal Neonatal Medicine*. 2004; 15: 186-192. (1.4) (**corresponding author**).
54. **Ning Y**, Williams MA, Dempsey J, Sorensen, T, Frederick I, Luthy D, Correlates of Recreational Physical Activity in Early Pregnancy, *J Maternal-Fetal Neonatal Medicine*. 2003; 13 (6): 385-393. (1.4) (**corresponding author**).
55. Wang W, **Ning Y**, Investigation of filariasis epidemics from 1957 to 1998 in Haikou, *Chinese Public Health*, Aug, 2000. 海口市1957~1998年丝虫病流行病学调查, *中国公共卫生*, 2000, 16(8).

56. Wang LX, Zhang XL, Zhu X, Cai F, **Ning Y**, Yu JJ, Wang KA. Analysis of Resident's Knowledge about Vaccination in Guangxi and Gansu Immunization. China Vaccination, May, 1998 广西壮族自治区和甘肃居民计划免疫知识现况分析 《中国计划免疫》 1998年 第5期.
57. Xu W, **Ning Y**, Wang W, The Evaluation of the Stop Smoking Intervention Study, Chinese Health Education, June, 1996.
58. Wang S, **Ning Y**, Li L, Experience and challenges in Big Data Interconnection of HealthCare. Chinese Journal of Epidemiology, March, 2020.
59. 佟明坤, 满塞丽麦, 金成、吴晶、单瑞琪、高永祥、王波、杨金刚、宁毅、李立明。千万例体检人群高血压患病率、知晓率、治疗率和控制率的调查. 中国循环杂志, 2020年9月第35卷 第九期 (总第267期) .
60. 陈璐, 潘焯, 刘秋萍, 林运欣, 王月清, 李烁宇, 孙点剑一, 吕筠, 王波, 余灿清, 宁毅, 李立明. .2008—2018年北京城区某健康体检人群饮酒行为变化趋势. 中华疾病控制杂志, 2021, 25(3): 284-288.
DOI:10.16462/j.cnki.zhjbkz.2021.03.007
61. 王月清, 孙点剑一, 潘焯, 刘秋萍, 林运欣, 李烁宇, 陈璐, 吕筠, 王波, 余灿清, 宁毅, 李立明. .2008—2018年北京城区某体检人群不健康饮食长期变化趋势. 中华疾病控制杂志, 2021, 25(3): 289-294.
DOI:10.16462/j.cnki.zhjbkz.2021.03.005
62. 郭呈华, 车晓玉, 林芝, 蔡珊, 刘国臻, 潘焯, 吕筠, 王波, 金成, 高永祥, 余灿清, 宁毅, 李立明. 中国某健康体检人群痔流行病学特征分析. 北京大学学报 (医学版), 2021, 53(04): 1-5 (已接收)

BOOK CHAPTER OR NATIONAL GUIDELINES

63. Hu DY, Han YL, Ma CS et al (**Ning Y**作为执笔专家) 《中国心血管病一级预防指南》, Chinese Medical Association Heart Association, Chinese Rehabilitation Medicine Association Cardiac Prevention and Rehabilitation Professional Committee, Chinese Society of Gerontology and Geriatrics Cardiac Professional Committee, Chinese Medical Doctor Association Thrombosis Committee. October, 2020, Beijing.
64. Wu YL, et al (**Ning Y**作为主要执笔专家) 《中国真实世界研究指南》, Chinese Lung Tumor Research Association and WJP Medical Foundation, People's Health Publisher. 2018
65. 人力资源和社会保障部, 国家职业技能标准 职业编码: 4-14-02-05 老年人能力评估师 (2020年版) (作为主要执笔专家)
66. 宁毅 杨苜 季蕾主编, 《新华指数.体检人群健康大数据.糖尿病地图》, 新华社经济信息社, 2019
67. 宁毅 杨苜 季蕾主编, 《新华指数.体检人群心血管健康报告》, 新华社经济信息社, 2019
68. Ning Y, Wu Y, etc. Guideline for Real World Data Research (Book), People's Health Publisher, July 2018
69. **Ning Y**, Wang B, Jin C, etc. China Health Index: Diabetes Big data Research; Xinhua News Publisher. Aug, 2019.
70. **Ning Y**, Wang B, Jin C, etc. China Health Index: Cardiovascular Health Big data Research; Xinhua News Publisher. Jan, 2020.

71. **Ning Y**, Zhao J, Evidence generation throughout the product journey (Chapter), Evidence Generation in Pharmaceutical Industry. People's Health Publishing House, June, 2018 (Chinese).
72. Zhao J, **Ning Y**. Generate evidence for National Reimbursement Drug List, Book of Intelligence Medicine: Outstanding Examples of Medical Affairs, Science and Technology Publisher, June, 2017 (Chinese Version)
73. Tangerman R, **Ning Y**, et al. Review of Poliomyelitis Eradication Activities in China (WHO region report), World Health Organization Region Office for the Western Pacific, February 1998.

SELECTED ABSTRACT PUBLICATIONS OR PRESENTATIONS (by 2017 only)

74. **Ning Yi**, Data based evidence for medical decision, Chinese Medical Affairs Conference, Nov 4, 2017.
75. **Ning Yi**. Post-Marketing Clinical Trials: Case Studies. Module 4: Global Registration, Post-marketing Development and Commercial Perspectives, Chinese Course in Drug Development and Regulatory Sciences (CCDRS), Beijing, November 14-18, 2017.
76. **Ning Yi**. Product Life Cycle Management. Module 4: Global Registration, Post-marketing Development and Commercial Perspectives, Chinese Course in Drug Development and Regulatory Sciences (CCDRS). Beijing, November 14-18, 2017.
77. **Yi Ning**, Create Value by Generating Evidence, RWE China Summit: Journey of Reform, Shanghai, June 29-30, 2017
78. **Yi Ning**, How to conduct clinical research, G-Seminar for Physicians. Taiyuan, June 23, 2017
79. **Yi Ning**, Chair Person, the Section of Real Word Evidence Generation, Drug Information Association (DIA) Conference, Shanghai, May 21-24, 2017
80. **Yi Ning**, Present and Future of Real Word Evidence Generation, Drug Information Association (DIA) Conference, Shanghai, May 21-24, 2017
81. **Yi Ning**, Practice of Evidence Generation using secondary data, 2nd China Medical Affairs Conference, Beijing, April 16-24, 2017
82. **Y Ning**, Evidence Generation for Medical Practice, International Precision Medicine Convention (P4 China 2016), China Society of Biotechnology, Chinese Research Hospital Association, 16-18, December 2016, Beijing.
83. Zhao J, Parks D, Camejo RR, Cooper J, Ni E, **Yi Ning**. Indirect comparison of double-blinded, randomised controlled trials: comparative efficacy and safety of Ropinirole-SR vs. Pramipexole as adjunctive therapies to levodopa for the management of advanced Parkinson's disease, The 4th Congress of Neuro-Degenerative Diseases Committee (NDDC), Chinese Society of Microcirculation, Beijing, Oct 14-16, 2016.
84. Samyshkin Y, Yi B, Shi C, Camejo RR, **Yi Ning**, Zhao J. Cost analysis for Ropinrole SR and Pramipexole adjunctive therapy in patients with advanced Parkinson's Disease in China, The 4th Congress of Neuro-Degenerative Diseases Committee (NDDC), Chinese Society of Microcirculation, Beijing, Oct 14-16, 2016.
85. **Ning Y**, Real World Data for Evidence-Based Medicine: An industry perspective to consolidate value, evidence, and outcome, The 8th DIA China Annual Meeting, Beijing, May 15-18, 2016.

86. **Ning Y**, Maximize Medical Affairs Values to Patients and Stakeholders, China Medical Affairs Network, March 110-11, Shanghai. Four Topics: 1) Study design for Patient Registry, 2) Improvement of Study Quality, 3) Interpreting Results as an Author or Reader; and 4) Real case discussion.
87. **Ning Y**, Clinical Research Using Clinical Data, Boston Physician Meeting in Shanghai, Shanghai. Jan 30, 2016.
88. **Ning Y**, From traditional epidemiology research to evidence generation using big-data approaches, Conference of Medical Big-Data Research, Dec 8, 2015, Shanghai.
89. Zhao H*, Yang S, Yi B, Peng M, **Ning Y**, invited speaker, Is hormone replacement therapy associated with age-related macular degeneration? A systematic review and meta-analysis, the 5th International Conference on Neurology & Epidemiology, November 18-20, 2015, Gold Coast, Australia.
90. **Ning Y**, How to conduct clinical research for clinicians, G-Seminar, Nov 10, 2015, Nanjing.
91. **Ning Y**, Use medical data to conduct research, G-Seminar, June 10, 2016, Shanghai.
92. **Ning Y**, Invited Speaker, Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in patients with myocardial infarction, Great Wall CVD conference, Oct 29-Nov 1, 2015, Beijing.
93. **Ning Y**. Overcoming Challenges and Complexities of Evidence Based Practice. ChinaMeRA Pharmaceutical Science Training, Aug 3, 2015, Shanghai.
94. Yang S, **Ning Y**. Introduction to Pharmacoeconomic Studies. ChinaMeRA Pharmaceutical Science Training, Aug 3, 2015, Shanghai.
95. Zhao H, **Ning Y**. Epidemiology Forecasting Models. China MeRA Pharmaceutical Science Training, Aug 3, 2015, Shanghai.
96. **Ning Yi**, Evidence Review of Whole Grain and Disease Prevention, Conference of Whole Grain Foods organized, National Nutrition Promotion Program Office. July 26, 2015, HangZhou. (Interview by CCTV was followed).
97. **Ning Y**, Invited speaker, Why Did Meta-Analysis Give a False Alarm? Landscape analysis in strategic planning of study design in drug development, International Chinese Statistics Association, July 7-8, 2015, Shanghai.
98. **Ning Yi**, Invited Speaker, Cancer Nutrition and Future Medicine, Harbin Medical University, June 28, 2015. Harbin.
99. **Ning Y**, Evidence-Based Medicine and Big Data, TEDx Lujiazu, June 14, 2015, Shanghai.
100. **Ning Y**, (Organizer/Chairperson), Meta-Analysis: Theory, Application, and Caveats, 2014 Quantitative Science Forum: Quantitative Drug Evaluation in and, Beyond Clinical Trials, Oct 31-Nov 1, 2014, Beijing.
101. **Ning Y**, Personalized Health Management, China Medical Association Conference, China Medical Association, Beijing, Nov 22-23, 2014.
102. **Ning Y**, Evidence-Based Medicine to Personalized Lifestyle Management, Hejun Business School, Trends of New Health Industry, September 21, Shanghai.
103. **Ning Y**, Application of Big Data in Health Industry, the New York China Forum, Nov 4, 2014, Shanghai.
104. **Ning Y**. Finding the right number: Re-estimation of Chinese Hepatitis C Prevalence. SciNovations Symposium, GlaxoSmithKline, Upper Merion, PA, Feb 19, 2014.

105. **Ning Yi**, Herrick K, Anscher M, Mikkelsen M, Lapane K. Cause of death in cancer survivors, American Association for Cancer Research 2012 scientific session (*News release by AACR conference*).
106. Helou M*, Liu H, **Ning Y**, Sisler I. Is Obesity Alone Associated with Increased Blood Cell Counts in Otherwise Healthy Children? American Society of Hematology 53rd Annual Meeting, San Diego, CA. December 10-13, 2011. (** Mentored student, received Poster Award*) <http://www.hematology.org/Awards/Award-Recipients/Abstract-Achievement/3309.aspx>
107. **Ning, Y.** Troeschel A, Herrick K, Taylor S, Owens M, K. Lapane K. Comparison of Sleep Duration between Cancer Survivors and Cancer-Free Individuals: Findings from NHANES Study. Society for Epidemiologic Research, 2012 conference.
108. **Ning Y.**, Phillips A. Helou M, Herrick K, Rafie C, Lu N, . Lapane K. Physical Activity and Sedentary Behavior in Cancer Survivors: Findings from NHANES, Society for Epidemiologic Research 2012 conference, 2012.
109. Engeda J*, Mezuk B, Ratliff S, and **Ning Y.** Sleep and Diabetes Status: Evidence from NHANES. Society for Epidemiologic Research 2012 conference, 2012.
110. Wickham E*, Jones R, Sylvester C, Evans R, Bean M, **Ning Y.** Comparison of 48- and 24-hour Dietary Recall Methods in Predicting Changes in Body Mass among Overweight Adolescents Enrolled in a Multidisciplinary Weight Management Program, Pediatric Academic Societies Annual Meeting, 2012.
111. **Ning Y**, Shibing Yang, s, Herrick K, Lapane K, Body Size and Postprandial Glucose Levels -- should the diagnosis criteria of type 2 diabetes consider height? American Diabetes Association 2012 scientific session.
112. News Report, Cancer Survivors: Nearly Half Eventually Die of Something Other than Cancer, Oncology Times Issue: Volume 34(10), 25 May 2012, p16.
113. Song Y*, Yeung E, Liu A, VanderWeele TJ, Chen L, Liu C, Schisterman EF, **Ning Y**, Zhang C* Pancreatic Beta-cell function and type 2 diabetes risk: quantify the causal effect using a Mendelian randomization approach based on meta-analyses, American Diabetes Association 2012 scientific session.
114. Helou M*, **Ning Y.** Massey G, Francis G, Godder K, Laver J. Vitamin D Deficiency in the Pediatric Oncology Population: Defining Who is at Risk and the Need for Standardized Screening. American Society of Clinical Oncology Meeting, Chicago, IL May 30 - June 3, 2010. (** Mentored student, Travel Award*)
115. **Ning Y**, Lifestyle Management for Cancer Survivors, Virginia Commonwealth University Medical School, May, 2010.
116. **Ning Y**, Metabolic disorders and Cancer, Virginia Commonwealth University Medical School seminar, Feb, 2010.
117. **Ning, Y;** Wu, K; Ma, J, et al. Concentrations of C-peptide, Insulin, Insulin-Like Growth Factor(IGF)-I, and AGF Binding Proteins (IGFBP) and The Risk of Colorectal Cancer in Men and Women. 43rd Annual Meeting of the Society-for-Epidemiologic-Research, Date: JUN 23-26, 2010, American Journal of Epidemiology, 171 S59, 2010
118. **Ning Y**, Metabolic disorders and colorectal and prostate cancer, Johns Hopkins University Center for Human Nutrition, October, 2009.
119. **Ning Y**, Giovannucci E, Wang L. Body mass index and colorectal cancer: a meta-analysis and systematic review, American Association for Cancer Research Annual Meeting 2008, San Diego, 2008.
120. **Ning Y**, Iron Fortification in China: From Science to Practice. Harvard School of Public Health, May, 2006.

121. Noble A, **Ning Y**, Woelk GB, Mahomed K, Williams MA. Preterm delivery risk in relation to maternal HIV infection, history of malaria and other infections among urban Zimbabwean women. Society for Pediatric and Perinatal Epidemiologic Research, Toronto, Canada. June 2005.
122. Pham L, Woelk GB, **Ning Y**, Madzime S, Mudzamiri S, Mahomed K, Williams MA. Seroprevalence and risk factors of syphilis infection in pregnant women delivering at Harare Maternity Hospital, Zimbabwe. Society for Pediatric and Perinatal Epidemiologic Research, Toronto, Canada. June 2005.
123. Ayana R, Woelk GB, Mohamed K, **Ning Y**, Williams MA. Risk factors for preterm delivery among Zimbabwean women. Society for Pediatric and Perinatal Epidemiologic Research, Toronto, Canada. June 2005.
124. **Ning Y**, Oken E, Rifas-Shiman S, Rich-Edwards JW, Gillman MW, Diet During Pregnancy And Risk For Gestational Hypertension Or Preeclampsia, the Second International Conference on Women, Heart Disease & Stroke, in Orlando, Florida, February, 2005. CIRCULATION Volume: 111 Issue: 4 Pages: E77-E77 Published: 2005
125. Ogbonna C, Woelk GB, **Ning Y**, Mudzamiri S, Mohamed K, Williams MA. Maternal Mid-Arm and Other Anthropometric Measures of Adiposity in Relation to Infant Birth Size among Zimbabwean Woman. Society for Pediatric and Perinatal Epidemiologic Research, Toronto, Canada. June 2005.
126. **Ning Y**, Williams MA, Dempsey J, Sorensen, T, Frederick I, Luthy D, Determinants of Recreational Physical Activity in Early Pregnancy, Society for Pediatric and Perinatal Epidemiologic Research, Atlanta, GA. June 2003.
127. **Ning Y**, Jim D. The Effects of the Interval between Pregnancies on Low Birth Weight, Washington Society for Epidemiologic Research, Seattle, Washington, 2000.
128. **Ning Y**, Poliomyelitis Epidemiology and Control, China-Myanmar-WHO-UNICEF Conference on Vaccination Campaign, Myanmar, Oct., 1996.
129. **Ning Y**, Chairman China-Myanmar-WHO-UNICEF Conference on Vaccination Campaign, Myanmar, Oct., 1996.

(By 2017)

300年历史医药巨擘葛兰素史克有类似于科学院的特殊Fellow制度，这是收到获得Senior Fellow的贺信：

Attachment 1: Announcement /Congratulation Letter from GSK Leader (May 2017)

Senior Fellow is the highest academic ladder at GSK R&D. GSK Fellows are leaders in R&D who are brilliant at their scientific disciplines and who become aspirational beacons that motivate people to excel technically and that attract and excite talented scientists. As leaders, GSK Fellows act as ambassadors to advocate for Scientists in R&D and are the 'go to' network for scientific consulting and cross discipline collaboration and connectivity.

Bing翻译：Senior Fellow是葛兰素史克研发的最高学术阶梯，葛兰素史克研究员是研发领域的领导者，他们在科学学科方面非常出色，并成为激励人们在技术上出类拔萃并吸引和激发才华横溢的科学家的有抱负的灯塔。作为领导者，葛兰素史克研究员担任大使，倡导研发领域的科学家，是科学咨询和跨学科合作与互联互通的“首选”网络。

I am very pleased to announce the second wave of ID TAU scientists to be elected to the GSK Society of Fellows. The Fellows program recognize excellence in scientific achievement and leadership. To merit election to the Society of Fellows, nominees are required to meet rigorous criteria in the following areas: (1) scientific track record; (2) visibility and credibility; (3) scientific leadership/impact of scientific knowledge on R&D and (4) contributions to GSK and Societies. Fellows are expected to demonstrate these criteria on an ongoing basis and to continue to develop their scientific capabilities and prowess over time, in addition to mentoring other scientists across R&D. Please join me in congratulating the following individuals for this prestigious recognition:

Bing翻译：研究员计划旨在表彰在科学成就和领导力方面的卓越表现。为了有资格当选为研究员协会会员，被提名人必须符合以下领域的严格标准：（1）科学记录；（2）知名度和可信度；（3）科学领导力/科学知识对研发的影响，（4）对葛兰素史克和社会的贡献。预计研究员将持续展示这些标准，并随着时间的推移继续发展他们的科学能力和实力，此外还将指导其他科学家进行研发。请和我一起祝贺以下个人获得这一享有盛誉的认可：

Yi Ning (Senior Fellow, IIDPH): Yi has an excellent track record of applying multidisciplinary knowledge and expertise to impact discovery and development policy, processes and guidelines in the pharmaceutical industry. He was a well-funded Investigator and professor before joining GSK and has prepared >50 national policy documents/guidelines and has >80 publications. He currently holds visiting professorships at several universities. As a former national disease surveillance expert in China, he partnered with experts to develop multiple disease prevention and treatment guidelines. During his 3 years at GSK, he has initiated, led and directed multiple programs, including (1) developing new research approaches to identify promising drugs and pathways for prevention and treatment of neuro-diseases; (2) devising a template and protocol guidelines for an intensive drug monitoring program, (3) developing a strategic plan for evidence generation with 3 publications in 10 months to support the ReQuip national reimbursement drug list application which may increase patient's access to the medicine by 15-20 fold; (4) initiating Seretide phase IV studies in China (involving first time use of a national health insurance claims database in China); (5) identified existing databases to conduct clinical studies in a timely and cost-effective manner; and (6) directed study design of clinical trials in China and developed > 120 epidemiological packages in multiple TAs. Yi is a well-respected epidemiologist and senior advisor in the pharmaceutical industry, is one of the Founders and Board Directors of the China Health Policy and Management Society, a former Prospective Editor of China Health Review and editor of several journals. Yi is one of only a few GSK-certified scientific speakers for continuing medical education in China.

Bing翻译：宁毅在应用多学科知识和专业知识来影响制药行业的发现和开发政策，流程和指南方面拥有出色的记录。在加入葛兰素史克之前，他是一名资金雄厚的调查员和教授，准备了>50份国家政策文件/指南，并发表了>80篇论文。他目前在多所大学担任客座教授。作为中国前国家疾病监测专家，他与专家合

作制定了多种疾病预防和治疗指南。在葛兰素史克的3年中，他发起，领导和指导了多个项目，包括（1）开发新的研究方法，以确定预防和治疗神经疾病的有前途的药物和途径；（2）为强化药物监测计划设计模板和协议指南，（3）制定证据生成战略计划，在10个月内发布3份出版物，以支持 ReQuip 国家报销药物清单申请，该申请可能使患者获得药物的机会增加 15-20 倍；（4）在中国启动 Seretide IV 期研究（涉及首次使用中国的国家健康保险索赔数据库）；（5）确定现有数据库，以便及时和具有成本效益地进行临床研究；（6）指导中国临床试验的研究设计，开发了>多个 TA 的 120 个流行病学包。宁毅是制药行业备受尊敬的流行病学家和高级顾问，是中国卫生政策与管理学会的创始人和董事会成员之一，曾任《中国卫生评论》的准编辑和多家期刊的编辑。宁毅是中国为数不多的获得葛兰素史克认证的继续医学教育科学演讲者之一。